179 related articles for article (PubMed ID: 35959620)
21. Cancer progression and substance P.
Coveñas R; Muñoz M
Histol Histopathol; 2014 Jul; 29(7):881-90. PubMed ID: 24535838
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment for multiple-day anthracycline-induced nausea and vomiting.
Li Q; Wu Y; Wang W; Deng S; Jiang C; Chen F; Zhao J; Li H; Bai X; Hou J; Da L; Zhao L; Gao J; Jin G
Curr Probl Cancer; 2019 Dec; 43(6):100462. PubMed ID: 30709557
[TBL] [Abstract][Full Text] [Related]
23. Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach.
Muñoz M; Coveñas R
Saudi J Gastroenterol; 2016; 22(4):260-8. PubMed ID: 27488320
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor.
Watanabe Y; Asai H; Ishii T; Kiuchi S; Okamoto M; Taniguchi H; Nagasaki M; Saito A
J Pharmacol Sci; 2008 Jan; 106(1):121-7. PubMed ID: 18187929
[TBL] [Abstract][Full Text] [Related]
25. Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials.
Navari RM
Cancer Invest; 2004; 22(4):569-76. PubMed ID: 15565815
[TBL] [Abstract][Full Text] [Related]
26. The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines.
Muñoz M; Rosso M; Coveñas R
Pharmacol Rep; 2017 Aug; 69(4):696-701. PubMed ID: 28550801
[TBL] [Abstract][Full Text] [Related]
27. Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug.
Kast RE
J Clin Pharm Ther; 2010 Dec; 35(6):657-63. PubMed ID: 21054456
[TBL] [Abstract][Full Text] [Related]
28. Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro.
Wang X; Douglas SD; Lai JP; Tuluc F; Tebas P; Ho WZ
J Neuroimmune Pharmacol; 2007 Mar; 2(1):42-8. PubMed ID: 18040825
[TBL] [Abstract][Full Text] [Related]
29. The NK-1R Antagonist Aprepitant Prevents LPS-Induced Oxidative Stress and Inflammation in RAW264.7 Macrophages.
Zhao XN; Bai ZZ; Li CH; Sheng CL; Li HY
Drug Des Devel Ther; 2020; 14():1943-1952. PubMed ID: 32546961
[TBL] [Abstract][Full Text] [Related]
30. Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo.
Wu H; Cheng X; Huang F; Shao G; Meng Y; Wang L; Wang T; Jia X; Yang T; Wang X; Fu C
Drug Des Devel Ther; 2020; 14():2413-2422. PubMed ID: 32606608
[TBL] [Abstract][Full Text] [Related]
31. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.
Rapoport BL; Aapro M; Chasen MR; Jordan K; Navari RM; Schnadig I; Schwartzberg L
Drug Des Devel Ther; 2017; 11():2621-2629. PubMed ID: 28919712
[TBL] [Abstract][Full Text] [Related]
32. Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation.
Cao X; Yang Y; Zhou W; Wang Y; Wang X; Ge X; Wang F; Zhou F; Deng X; Miao L
BMC Cancer; 2023 May; 23(1):471. PubMed ID: 37221457
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant for nausea and vomiting induced by cisplatin and carboplatin in Japanese patients with gynecological cancer.
Ikeda M; Shida M; Hirasawa T; Muramatsu T; Mikami M
J Obstet Gynaecol Res; 2017 Oct; 43(10):1613-1620. PubMed ID: 28691209
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy.
Jordan K; Kinitz I; Voigt W; Behlendorf T; Wolf HH; Schmoll HJ
Eur J Cancer; 2009 May; 45(7):1184-1187. PubMed ID: 19135359
[TBL] [Abstract][Full Text] [Related]
35. Neurokinin-1 Receptor Antagonists against Hepatoblastoma.
Muñoz M; Rosso M; Coveñas R
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31466222
[TBL] [Abstract][Full Text] [Related]
36. Clinical Efficacy of Aprepitant in Patients with Gynecological Cancer after Chemotherapy Using Paclitaxel and Carboplatin.
Maehara M; Ueda T; Miyahara D; Takahashi Y; Miyata K; Nam SO; Katsuda T; Kondo H; Miyamoto S
Anticancer Res; 2015 Aug; 35(8):4527-34. PubMed ID: 26168497
[TBL] [Abstract][Full Text] [Related]
37. The Use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer.
Martín-García D; Téllez T; Redondo M; García-Aranda M
Curr Med Chem; 2023 Oct; ():. PubMed ID: 37861026
[TBL] [Abstract][Full Text] [Related]
38. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Opin Investig Drugs; 2007 Dec; 16(12):1977-85. PubMed ID: 18042005
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of aprepitant for CHOP chemotherapy-induced nausea, vomiting, and anorexia.
Morita M; Kishi S; Ookura M; Matsuda Y; Tai K; Yamauchi T; Ueda T
Curr Probl Cancer; 2017; 41(6):419-425. PubMed ID: 29061362
[TBL] [Abstract][Full Text] [Related]
40. NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.
Muñoz M; Martinez-Armesto J; Coveñas R
Expert Opin Ther Pat; 2012 Jul; 22(7):735-46. PubMed ID: 22697287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
